{"doi":"10.1016/j.nicl.2018.09.025","title":"White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients","abstract":null,"journal":"NeuroImage: Clinical","year":2018,"id":642159,"datarank":0.6456097639806255,"base_score":4.304065093204169,"endowment":4.304065093204169,"self_citation_contribution":0.6456097639806255,"citation_network_contribution":0.0,"self_endowment_contribution":0.6456097639806255,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":73,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":445140,"name":"Yashar Zeighami","orcid":"0000-0002-0583-5811","position":1,"is_corresponding":false},{"id":685946,"name":"Yvonne Yau","orcid":null,"position":2,"is_corresponding":false},{"id":22486,"name":"Seyed-Mohammad Fereshtehnejad","orcid":null,"position":3,"is_corresponding":false},{"id":316576,"name":"Josefina Maranzano","orcid":"0000-0002-9696-5522","position":4,"is_corresponding":false},{"id":108592,"name":"Ronald B. Postuma","orcid":"0000-0002-6468-4734","position":5,"is_corresponding":false},{"id":239707,"name":"Alain Dagher","orcid":"0000-0002-0945-5779","position":6,"is_corresponding":false},{"id":194852,"name":"D. Louis Collins","orcid":"0000-0002-8432-7021","position":7,"is_corresponding":false},{"id":301640,"name":"Mahsa Dadar","orcid":"0000-0003-4008-2672","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients","abstract":"White Matter Hyperintensities (WMHs) are associated with cognitive decline in aging and Alzheimer's disease. However, the pathogenesis of cognitive decline in Parkinson's disease (PD) is not as clearly related to vascular causes, and therefore the role of WMHs as a marker of small-vessel disease (SVD) in PD is less clear. Currently, SVD in PD is assessed and treated independently of the disease. However, if WMH as the major MRI sign of SVD has a higher impact on cognitive decline in PD patients than in healthy controls, vascular pathology needs to be assessed and treated with a higher priority in this population. Here we investigate whether the presence of WMHs leads to increased cognitive decline in de novo PD, and if these effects relate to cortical atrophy. WMHs and cortical thickness were measured in de novo PD patients and age-matched controls (N<sub>PD</sub> = 365, N<sub>Control</sub> = 174) from Parkinson's Progression Markers Initiative (PPMI) to study the relationship between baseline WMHs, future cognitive decline (follow-up: 4.09 ± 1.14 years) and cortical atrophy (follow-up: 1.05 ± 0.10 years). PD subjects with high baseline WMH loads had significantly greater cognitive decline than i) PD subjects with low WMH load, and ii) control subjects with high WMH load. Furthermore, in PD subjects, high WMH load resulted in more cortical thinning in the right frontal lobe. Theses results show that the presence of WMHs in de novo PD patients predicts greater future cognitive decline and cortical atrophy than in normal aging.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"30292088","pmcid":"PMC6176552","openalex_id":null,"authors":[],"funders":[{"funder_name":"Canadian Institutes of Health Research","grant_id":"MOP-111169","title":null},{"funder_name":"Natural Sciences and Engineering Research Council of Canada","grant_id":"4140438 - 2012","title":null},{"funder_name":"Natural Sciences and Engineering Research Council of Canada","grant_id":"unidentified","title":"unidentified"},{"funder_name":"Michael J. Fox Foundation for Parkinson&amp;apos;s Research","grant_id":"","title":null},{"funder_name":"Parkinson Society Canada","grant_id":"","title":null},{"funder_name":"Canada Foundation for Innovation","grant_id":"","title":null},{"funder_name":"Garfield Weston Foundation","grant_id":"","title":null},{"funder_name":"R. Howard Webster Foundation","grant_id":"","title":null},{"funder_name":"Government of Canada","grant_id":"","title":null},{"funder_name":"Weston Brain Institute","grant_id":"","title":null}],"total_grants":10,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://www.sciencedirect.com/science/article/pii/S2213158218303000/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2213158218303000?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2213158218303000?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doaj.org/article/84606162ee9143e2a026540ad7874b85","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC6176552","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC6176552?pdf=render","host_type":"Europe_PMC"},{"url":"https://doi.org/10.1016/j.nicl.2018.09.025","host_type":""},{"url":"https://pubmed.ncbi.nlm.nih.gov/30292088","host_type":""},{"url":"http://dx.doi.org/10.1016/j.nicl.2018.09.025","host_type":""},{"url":"https://dx.doi.org/10.1016/j.nicl.2018.09.025","host_type":""}],"fields_of_study":["03 medical and health sciences","0302 clinical medicine"],"mesh_terms":["Frontal Lobe","Humans","Parkinson Disease","Atrophy","Magnetic Resonance Imaging","Neuropsychological Tests","Aging","Aged","Aged, 80 and over","Middle Aged","Female","Male","White Matter","Cognitive Dysfunction"],"keywords":["Magnetic Resonance Imaging","Parkinson's Disease","Cognitive Decline","White Matter Hyperintensities","De Novo Patients","Male","Aging","Computer applications to medicine. Medical informatics","150","R858-859.7","610","Neuropsychological Tests","Humans","Cognitive Dysfunction","RC346-429","Aged","Aged, 80 and over","Regular Article","Parkinson Disease","Middle Aged","White Matter","Frontal Lobe","Female","Neurology. Diseases of the nervous system","Atrophy"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T21:44:59.497788Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}